Preparative and Process Chromatography Market Projected to Reach $29.53 Billion by 2035, Driven by Biologics Manufacturing Boom
Key Insights
The global preparative and process chromatography market is projected to grow from $13.74 billion in 2025 to $29.53 billion by 2035, at a CAGR of 8.20%.
North America held the largest market share at approximately 34.55% in 2025, with the U.S. market alone expected to reach $7.28 billion by 2035.
The biopharmaceutical industry remains the dominant end-user segment, accounting for 43.56% of revenue, driven by monoclonal antibody and recombinant protein production.
The global preparative and process chromatography market is on a robust growth trajectory, with market valuation expected to climb from $13.74 billion in 2025 to $29.53 billion by 2035, expanding at a compound annual growth rate (CAGR) of 8.20%, according to a report by SNS Insider. This growth is fueled by surging biologics production, increasing demand for downstream purification technologies, and expanding biopharmaceutical manufacturing capacity worldwide.
Preparative and process chromatography encompasses advanced separation and purification techniques critical to isolating, purifying, and recovering valuable compounds from complex mixtures. These technologies are indispensable across pharmaceutical, biotechnology, food and beverage, and chemical industries, where product purity, quality, and regulatory compliance are paramount.
Market Dynamics and Segment Leadership
In 2025, the process chromatography segment commanded the largest revenue share at 68.46%, reflecting its essential role in commercial-scale production of antibodies, vaccines, and recombinant proteins (search) requiring GMP-validated purification systems. Meanwhile, the preparative chromatography segment is projected to register the fastest CAGR of 8.53% through 2035, driven by rising drug discovery programs and personalized medicine approaches demanding flexible small-batch purification capabilities.
Liquid chromatography held the dominant position among chromatography types, capturing 31.20% of revenue in 2025, owing to its broad applicability across ion exchange, size exclusion, hydrophobic interaction, and reversed-phase purification methods. Affinity chromatography is expected to grow at the highest rate during the forecast period, propelled by universal adoption of Protein-A (search) affinity capture in monoclonal antibody and biosimilar production.
Application and End-User Trends
Monoclonal antibodies (search) and recombinant proteins (search) represented the largest application segment with 39.30% of revenue in 2025, underpinned by large-scale biologics manufacturing and sustained biosimilar production investment. The cell and gene therapies segment is anticipated to register the fastest CAGR through 2035, as rapid expansion of viral vector, plasmid DNA, and mRNA purification requirements create demand for specialized chromatography technologies.
The biopharmaceutical industry remained the leading end-user, accounting for 43.56% of market revenue in 2025, driven by large-scale manufacturing programs, stringent GMP requirements, and growing pipelines of biologics and advanced therapy medicinal products. Contract research organizations are expected to grow at the fastest rate, fueled by progressive pharmaceutical outsourcing of drug discovery and clinical manufacturing.
Regional Landscape
North America dominated the global market with approximately 34.55% share in 2025, supported by a strong biopharmaceutical ecosystem, high R&D investments, and the commercial concentration of leading chromatography suppliers including Thermo Fisher Scientific (search), Danaher (Cytiva), MilliporeSigma, Bio-Rad, Waters, and Agilent. The U.S. market alone was valued at $3.38 billion in 2025 and is projected to reach $7.28 billion by 2035, growing at a CAGR of 7.94%.
Europe held a significant position, with its market valued at $3.85 billion in 2025 and projected to reach $7.97 billion by 2035 at a CAGR of 7.55%. The region serves as a global center of process chromatography technology development, anchored by Cytiva's Swedish headquarters, Sartorius AG (search)'s German operations, and Merck KGaA's German base.
Asia Pacific emerged as the fastest-growing regional market at a CAGR of 9.03% during 2026–2035, driven by expanding pharmaceutical manufacturing across China, India, Japan, and South Korea. China alone accounts for approximately 44.8% of Asia Pacific revenues, reflecting extraordinary biopharmaceutical capacity expansion.
Technological Advancements Shaping the Future
Continuous chromatography commercialization is improving resin utilization by 80–90% compared to batch operations, representing one of the most commercially transformative near-term opportunities. Single-use technologies, including disposable columns and filtration systems, are gaining traction due to their operational flexibility and contamination control benefits. Additionally, the integration of automation and digital monitoring technologies is enabling real-time process control, reducing human intervention, and enhancing overall manufacturing efficiency.
Recent industry developments include Sartorius AG (search)'s 2025 expansion of its chromatography portfolio with advanced purification technologies for biologics and cell therapy manufacturing, and Repligen Corporation's launch of enhanced chromatography solutions supporting high-throughput downstream bioprocessing.
As investments in life sciences research expand and personalized medicine gains momentum, preparative and process chromatography will remain a critical purification technology, ensuring product quality, regulatory compliance, and innovation across pharmaceutical, biotechnology, and industrial applications.